385 related articles for article (PubMed ID: 6328660)
21. An overview of the human T-lymphotropic retroviruses and the role of HTLV-III/LAV in AIDS.
Gurgo C; Robert-Guroff M; Gallo RC
Antibiot Chemother (1971); 1987; 38():1-12. PubMed ID: 2821878
[No Abstract] [Full Text] [Related]
22. Molecular cloning of lymphadenopathy-associated virus.
Alizon M; Sonigo P; Barré-Sinoussi F; Chermann JC; Tiollais P; Montagnier L; Wain-Hobson S
Nature; 1984 Dec 20-1985 Jan 2; 312(5996):757-60. PubMed ID: 6096717
[TBL] [Abstract][Full Text] [Related]
23. Isolation of human T-lymphotropic retrovirus (LAV) from Zairian married couple, one with AIDS, one with prodromes.
Ellrodt A; Barre-Sinoussi F; Le Bras P; Nugeyre MT; Palazzo L; Rey F; Brun-Vezinet F; Rouzioux C; Segond P; Caquet R
Lancet; 1984 Jun; 1(8391):1383-5. PubMed ID: 6145837
[TBL] [Abstract][Full Text] [Related]
24. Adaptation of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines.
Montagnier L; Gruest J; Chamaret S; Dauguet C; Axler C; Guétard D; Nugeyre MT; Barré-Sinoussi F; Chermann JC; Brunet JB
Science; 1984 Jul; 225(4657):63-6. PubMed ID: 6328661
[TBL] [Abstract][Full Text] [Related]
25. HTLV-III/LAV antibody and immune status of household contacts and sexual partners of persons with hemophilia.
Jason JM; McDougal JS; Dixon G; Lawrence DN; Kennedy MS; Hilgartner M; Aledort L; Evatt BL
JAMA; 1986 Jan; 255(2):212-5. PubMed ID: 3001375
[TBL] [Abstract][Full Text] [Related]
26. Analysis of effector mechanisms against HTLV-I- and HTLV-III/LAV-infected lymphoid cells.
Ruscetti FW; Mikovits JA; Kalyanaraman VS; Overton R; Stevenson H; Stromberg K; Herberman RB; Farrar WL; Ortaldo JR
J Immunol; 1986 May; 136(10):3619-24. PubMed ID: 2422259
[TBL] [Abstract][Full Text] [Related]
27. Persistent infection of chimpanzees with human T-lymphotropic virus type III/lymphadenopathy-associated virus: a potential model for acquired immunodeficiency syndrome.
Fultz PN; McClure HM; Swenson RB; McGrath CR; Brodie A; Getchell JP; Jensen FC; Anderson DC; Broderson JR; Francis DP
J Virol; 1986 Apr; 58(1):116-24. PubMed ID: 3005641
[TBL] [Abstract][Full Text] [Related]
28. HTLV-III/LAV and the origin and pathogenesis of AIDS.
Gallo RC; Robert-Guroff M; Wong-Staal F; Reitz MS; Arya SK; Streicher HZ
Int Arch Allergy Appl Immunol; 1987; 82(3-4):471-5. PubMed ID: 3032803
[No Abstract] [Full Text] [Related]
29. Survey of the prevalence of AIDS-associated virus (LAV) infection in Japan.
Tsuchie H; Kurimura T; Hinuma Y
J Infect; 1985 May; 10(3):272-6. PubMed ID: 2993425
[TBL] [Abstract][Full Text] [Related]
30. Immunologic abnormalities in the acquired immunodeficiency syndrome.
Lane HC; Fauci AS
Annu Rev Immunol; 1985; 3():477-500. PubMed ID: 2415141
[TBL] [Abstract][Full Text] [Related]
31. Evidence for HTLV-III/LAV expression by primary cultures of T8 cells.
Fouchard M; Reveil B; Mbayo K; Lurhuma A; Sarin PS; Gallo RC; Zagury D
Int J Cancer; 1986 Nov; 38(5):657-9. PubMed ID: 2945790
[TBL] [Abstract][Full Text] [Related]
32. [Activation of the macrophage/lymphocyte system in AIDS, ARC and AIDS risk groups].
Wachter H; Blecha HG; Fuchs D; Hausen A; Hengster P; Hinterhuber H; Reibnegger G; Reissigl H; Rössler H; Schönitzer D
Wien Klin Wochenschr; 1986 Jul; 98(14):449-54. PubMed ID: 3019018
[TBL] [Abstract][Full Text] [Related]
33. Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS.
Brun-Vézinet F; Rouzioux C; Montagnier L; Chamaret S; Gruest J; Barré-Sinoussi F; Geroldi D; Chermann JC; McCormick J; Mitchell S
Science; 1984 Oct; 226(4673):453-6. PubMed ID: 6238406
[TBL] [Abstract][Full Text] [Related]
34. Isolation of lymphadenopathy-associated virus (LAV) and detection of LAV antibodies from US patients with AIDS.
Barré-Sinoussi F; Mathur-Wagh U; Rey F; Brun-Vezinet F; Yancovitz SR; Rouzioux C; Montagnier L; Mildvan D; Chermann JC
JAMA; 1985 Mar 22-29; 253(12):1737-9. PubMed ID: 2983130
[TBL] [Abstract][Full Text] [Related]
35. Lymphadenopathy-associated virus: from molecular biology to pathogenicity.
Montagnier L
Ann Intern Med; 1985 Nov; 103(5):689-93. PubMed ID: 2996400
[TBL] [Abstract][Full Text] [Related]
36. A longitudinal study of patients with hemophilia: immunologic correlates of infection with HTLV-III/LAV and other viruses.
Stein SF; Evatt BL; McDougal JS; Lawrence DN; Holman RC; Ramsey RB; Spira TJ
Blood; 1985 Oct; 66(4):973-9. PubMed ID: 2994784
[TBL] [Abstract][Full Text] [Related]
37. HTLV-III/LAV antibodies and virus in hemophilia patients in Nebraska: survey and initiation of a prospective study.
Volsky DJ; Wu YT; Sinangil F; Goldsmith JC
AIDS Res; 1986 Feb; 2(1):51-61. PubMed ID: 2424467
[TBL] [Abstract][Full Text] [Related]
38. Restricted IgG subclass responses to HTLV-III/LAV and to cytomegalovirus in patients with AIDS and lymphadenopathy syndrome.
Sundqvist VA; Linde A; Kurth R; Werner A; Helm EB; Popovic M; Gallo RC; Wahren B
J Infect Dis; 1986 May; 153(5):970-3. PubMed ID: 3009638
[No Abstract] [Full Text] [Related]
39. Isolation of a lymphadenopathy-associated virus from a patient with the acquired immune deficiency syndrome.
Becker ML; Spracklen FH; Becker WB
S Afr Med J; 1985 Aug; 68(3):144-7. PubMed ID: 2992103
[TBL] [Abstract][Full Text] [Related]
40. Introduction of lymphadenopathy associated virus or human T lymphotropic virus (LAV/HTLV-III) into the male homosexual community in Amsterdam.
Coutinho RA; Krone WJ; Smit L; Albrecht-van Lent P; van der Noordaa J; Schaesberg W; Goudsmit J
Genitourin Med; 1986 Feb; 62(1):38-43. PubMed ID: 3005159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
